Research analysts at Royal Bank Of Canada initiated coverage on shares of Inovio Pharmaceuticals Inc (NASDAQ:INO) in a report issued on Wednesday. The firm set an “outperform” rating and a $11.00 price target on the biopharmaceutical company’s stock. Royal Bank Of Canada’s target price would suggest a potential upside of 76.57% from the stock’s current price.

A number of other equities research analysts have also recently commented on the stock. HC Wainwright reiterated a “buy” rating and set a $13.00 price target on shares of Inovio Pharmaceuticals in a report on Tuesday, September 12th. BidaskClub upgraded shares of Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Saturday, September 9th. Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price target on the stock in a report on Tuesday, July 11th. Maxim Group set a $12.00 price target on shares of Inovio Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. Finally, Aegis reiterated a “buy” rating and set a $14.00 price target on shares of Inovio Pharmaceuticals in a report on Tuesday, July 18th. Two analysts have rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average price target of $19.16.

Inovio Pharmaceuticals (NASDAQ:INO) traded down 0.32% during trading on Wednesday, reaching $6.23. The company’s stock had a trading volume of 869,299 shares. The company has a 50-day moving average of $6.22 and a 200 day moving average of $6.64. Inovio Pharmaceuticals has a one year low of $5.28 and a one year high of $9.86. The firm’s market cap is $562.11 million.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.21) by $0.08. The business had revenue of $20.41 million for the quarter, compared to analysts’ expectations of $16.29 million. Inovio Pharmaceuticals had a negative net margin of 46.44% and a negative return on equity of 33.16%. The business’s revenue was up 229.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.26) earnings per share. Analysts expect that Inovio Pharmaceuticals will post ($0.95) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another domain, it was stolen and reposted in violation of United States & international copyright and trademark law. The original version of this article can be read at https://www.dailypolitical.com/2017/10/20/royal-bank-of-canada-initiates-coverage-on-inovio-pharmaceuticals-inc-ino.html.

A number of hedge funds have recently modified their holdings of INO. Wasatch Advisors Inc. boosted its holdings in Inovio Pharmaceuticals by 43.6% in the second quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock worth $20,469,000 after purchasing an additional 793,306 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Inovio Pharmaceuticals by 7.9% in the first quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock worth $20,510,000 after purchasing an additional 226,861 shares during the last quarter. Candriam Luxembourg S.C.A. purchased a new stake in Inovio Pharmaceuticals in the second quarter worth approximately $1,411,000. GSA Capital Partners LLP purchased a new stake in Inovio Pharmaceuticals in the second quarter worth approximately $1,035,000. Finally, Virtu KCG Holdings LLC purchased a new stake in Inovio Pharmaceuticals in the second quarter worth approximately $556,000. Institutional investors own 24.83% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.